Dr. Reardon on the Potential Utility of INO-5401 and INO-9012 in Glioblastoma


In Partnership With:

David A. Reardon, MD, discusses the role of INO-5401 and INO-9012 in glioblastoma.

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, institute physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses the role of INO-5401 and INO-9012 in glioblastoma.

INO-5401 and INO-9012 are currently being evaluated in patients with newly diagnosed glioblastoma, says Reardon. Encouraging preliminary results were presented during the 2020 ASCO Virtual Scientific Program.

Notably, INO-5401 consists of three antigens that are highly expressed in glioblastoma tumor cells, including human telomerase, Wilms tumor protein, and prostate​-specific membrane antigen​, says Reardon. The hypothesis is that INO-5401 will induce an immune response ​in patients with glioblastoma.

Moreover, INO-9012 is engineered to express interleukin​-12 (IL-12), a molecule that plays an important role in attracting and activating dendritic cells, ​Reardon explains. ​

Ultimately, when the antigens are administered through INO-5401, IL-12 will bring in additional immune effector cells that could sensitize the immune system against these specific targets, Reardon concludes. 

Related Videos
John Shen, MD
Tatyana Feldman, MD
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center
Riccardo Lencioni, MD, FSIR, EBIR
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine